Hepatitis C Virus Prevalence, Medical Status Awareness and Treatment Engagement among Homeless People Who use Drugs: Results of a Street Outreach Study

Rinat Lasmanovich¹, Or Shaked¹, Ayelet Sivan¹, Idan Barak², Mor Nahari³, Orna Mor⁴ and Helena Katchman⁵

¹Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ²Israel AIDS task force, Israel.
³Faculty of Humanities and Social Sciences, Ben Gurion University, Beer Sheva, Israel.
⁴Central Virology Laboratory, Ministry of Health, Sheba Medical Center, Ramat-Gan, Israel.
⁵Department of Gastroenterology Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.

ABSTRACT

BACKGROUND: Hepatitis C virus (HCV) infection is a primary health concern among people who use drugs (PWUDs). Homeless PWUDs that constitute a key population for HCV transmission remain underrepresented in many surveys.

OBJECTIVES: We performed a proactive street outreach to evaluate HCV infection prevalence among homeless PWUDs in Tel Aviv, identify risk factors associated with HCV infection, awareness of disease status and linkage to care rate.

RESULTS: Thirty-eight percent of approached PWUD were willing to participate in the study. Out of 53 subjects who got tested for anti HCV by rapid test, 29 (54.72%) had a positive result, 20 of 29 anti-HCV positive (69%) patients had positive HCV PCR. Risk factors were investigated using structured questionnaires. Heroin use was reported significantly more frequently in the HCV-positive group (P= .05, CI 95%), whereas other established risk factors did not reach significance in our cohort. While 21 of 29 (72%) HCV-positive participants were aware of their condition, only 4 of 21 (19%) received treatment in the past, and 2 of 4 (50%) failed to achieve treatment goals, as assessed by HCV PCR.

CONCLUSIONS: Our data indicate a high prevalence of HCV infection among homeless PWUDs. Importantly, despite relatively high awareness of HCV status in this population, we found strikingly low access to care. These findings motivate novel interventional approaches targeted at improving patient access, and compliance among homeless PWUDs, in an effort to reduce HCV transmission.

KEYWORDS: Hepatitis C virus, people who use drugs, awareness, access to care, treatment

Introduction

Hepatitis C is a viral liver disease: the hepatitis C virus can cause both acute and chronic hepatitis and is a major cause of liver cancer. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. HCV is a bloodborne virus, transmitted primarily through exposure to blood or blood products. The most common modes of infection are through intravenous drug use, unsanitary health care procedures, transfusion of unscreened blood and blood products, and sexual practices that lead to blood exposure. Globally, an estimated 71 million people have chronic hepatitis C virus infection.

It is estimated that 12 million people worldwide inject drugs. Negative health outcomes of drug use can include drug use disorders, mental health disorders, Human Immunodeficiency Virus (HIV) infection, liver cancer and cirrhosis associated with hepatitis, overdose and premature death. The greatest harm to health is associated with opioid use, as it often involves drug injection, primarily due to the risk of acquiring HIV or HCV through unsafe injecting practices. In 2017, the joint UNODC, WHO and the UNAIDS estimated HCV prevalence among injecting drug users worldwide at 49.3%, which translates roughly to 5.6 million PWUDs living with HCV. In comparison, the prevalence of HCV in 2015 among the general population worldwide was estimated at 1.0% (range: 0.8%-1.1%).

Advances in treatment have led to higher cure rates than prior therapeutic approaches, showing high potency, favorable tolerability profile, higher barrier to resistance, shortened treatment duration, fewer drug interactions and reduced pill burden. The recent availability of highly tolerable new direct-acting antiviral (DAA) therapies has led to the development of World Health Organization HCV elimination targets, which proposed an 80% reduction in HCV incidence and a 65% reduction in HCV-related mortality by 2030. Thus, lack of tolerable and effective treatment is currently not a barrier to HCV eradication. Current barriers to achieving ambitious targets for
global HCV control include low awareness of infection among key populations such as PWUD, low treatment-seeking behavior among PWUD, lack of access to care, or low compliance with treatment regimens.

It should be noted that every Israeli resident is covered by health insurance which entitles him/her to the services established under the National Health Insurance Law. Lack of payment or delayed payment of health insurance fees does not affect the rights of a policyholder and does not exempt the health plan from providing the healthcare services included in The Healthcare Basket. Nevertheless, deductibles for insured patients may not be affordable for all strata of the population since the costs of Hepatitis C treatment is close to 300$. This obstacle may be overcome by receiving sponsored treatment, but the bureaucratic process may be cumbersome.

HCV prevalence, risk factors, and barriers to infection control among homeless PWUDs in Tel Aviv, Israel are not well understood. We sought to characterize these factors among this local population, in an effort to identify key avenues of intervention to increase HCV eradication in this community.

**Methods**

**Study population**

Subjects were recruited through street outreach by members of the Israel Aids Task Force (IATF) team and volunteers, from October 3rd, 2018, to November 14th, 2019. The area of activity was in the south Tel Aviv region, Israel.

All subjects declared being homeless (eg, with no permanent housing for at least 3 weeks) and current drug users, not being treated at any drug and addiction clinic except 3 individuals, who continued to use illicit drugs despite current opioid substitution therapy.

Fifty-three out of 142 participants agreed to be tested for HCV and HIV and filled out questionnaires. Results were obtained for 52 of 53 participants, as one blood sample was not tested due to insufficient quantity for proper testing.

**Study procedures**

Israeli Aids Task Force provided an ambulance with first aid equipment, sterile syringes and needles, food and hot drinks. As the subjects arrived at the ambulance, they were offered free HCV and HIV testing. Once one accepted to be tested, IATF staff and volunteers used structured interview questionnaires assessing HCV and HIV risk behaviors including drug use and sexual practices. For each subject, gender, country of origin, emigration date, drugs in use, duration of drug use, alcohol consumption, sexual practices (including safe sex and number of partners), HCV status awareness and previous HCV treatment were recorded.

Medical equipment included HCV rapid tests (OraQuick rapid test to detect antibodies [OraSure Technologies, Bethlehem, PA USA]) and HIV rapid tests (Chembio HIV 1/2 STAT-PAK [Chembio diagnostic systems, New-York, US]). Blood specimens were shipped to the Infectious Diseases Unit at Sheba Medical Center, quantitative HCV PCR and HCV Genotype detection tests (Abbott RealTime HCV assay) were performed in all blood samples. For HIV positive test results, Enzyme-Linked Fluorescent Assay (VIDAS DUO) was made on a repeat serum sample and HIV confirmation by Western Blot test.

**Statistical analysis**

All analyses were performed in SPSS version 25 (IBM SPSS Statistics, Chicago, IL, USA). The statistical analysis was carried out in several steps. First, a univariate exploration of study variables was done, and it included inspection of the normal distribution of continuous variables and error values and outliers. Overall patient characteristics were summarized by mean (standard deviation) for continuous variables and by frequency (%) for nominal variables. Next, characteristics were compared between the study groups by bivariate analysis. The student’s t-test and Wilcoxon rank-sum test were performed for comparison of normally and non-normally distributed continuous variables, while nominal variables were compared with the Chi-square test. Alpha and beta parameters were set at 0.05 and 0.2, respectively. A P-value was used for a convenient representation of statistical significance.

**Results**

Of 142 subjects who voluntarily approached the IATF ambulance, 53 (38%) participants agreed to be tested for HCV infection and fill out questionnaires. 89 (62%) subjects who approached IATF ambulance but refused to be tested, did not fill out questionnaires. Hence, qualitative data for these subjects are missing. Demographic characteristics for the 53 individuals are summarized in Table 1. The median age of participants was 41 (range 26–68 years). The mean age of drug use was 16 years (range 0–35 years of drug use). 37 (69%) subjects reported intravenous drug use, 9 (17%) reported using drugs by other practices such as sniffing, smoking, drinking, or swallowing and 3 (0.06%) refused to share that kind of information (Figure 1A). Drug type, alcohol use and sexual behavior are depicted in Figure 1B to E.

Fifty-two rapid tests to detect HCV and HIV based on whole blood specimens were performed. The prevalence of HCV exposure among homeless PWUDs was 56%, as 29 of 52 rapid HCV antibodies tests were positive. Positive viral load was detected in 20 out of 29 (69%) exposed patients as assessed by HCV PCR. All 23 patients that were negative by rapid antibody test were HCV PCR negative (100% specificity). One HIV rapid test reacted.

Genotype characterization was performed in 18 samples. Genotype 1a and genotype 3 were most common: 7 patients, 39% of each genotype, followed by genotype 1b in 4 patients (22%).
To identify risk factors associated with HCV infection, we compared HCV positive vs negative participants (Table 2). Both Anti-HCV positive and Anti-HCV negative had a male majority, with no age differences between the groups (44.7 vs 43.7, $P = .73$) nor differences related to the country of birth, with an equal number of immigrants from the former Soviet Union in the HCV-positive and HCV-negative groups (52% vs 52.6% respectively, $P = .96$). Among the immigrant group, the proportion of people that immigrated before 2010 was higher in HCV-positive participants compared to the HCV-negative group (93.5% vs 61.5%, $P = .06$).

Regarding mode of use, intravenous drug use was extremely common in all examined populations. Despite a higher rate of IVDU in the HCV-positive group vs the HCV-negative group (82.2% vs 61.9%), this difference did not reach statistical significance. Heroin use was reported significantly more frequently in the HCV-positive group compared with the HCV-negative group (85.7% vs 61.9%, $P = .05$). Participation in an opioid substitution therapy program, having 1 partner, practicing safe sex, were reported at a similar frequency in both groups.

Medical status awareness and access to care

Forty-five of all 53 subjects had medical insurance (84.9%), 1 had no medical insurance and 4 were unable to report insurance status. 23 out of 53 (43%), declared that they are aware of being carriers of hepatitis C (Figure 2). This self-reported HCV positive status was confirmed in 21 out of 23 subjects (91%) by positive results on a rapid HCV test. Based on PCR laboratory results, 14 out of these 21 subjects (67%), were HCV PCR positive, suggesting an active infection and the potential of disease transmission.

Out of 21 patients that claimed themselves as HCV infected and had an evidence of HCV exposure by a rapid test, only 4 (19%) subjects declared receiving trial of hepatitis C treatment (Figure 2). Two out of four treated patients (50%) were treated successfully as defined by a negative HCV PCR, while the other 2 failed to achieve treatment goals as defined by a positive HCV PCR result (Figure 2). Out of 29 patients that thought to be HCV negative or were unaware of their HCV status, 8 patients (27.5%) were diagnosed in the process of our research, and 6 of them were HCV PCR positive based on laboratory tests.

In summary, out of 29 anti-HCV positive patients, 21 (70%) were aware while 8 (30%) were unaware of hepatitis C infection.

Linkage to care of diagnosed individuals

Despite a full explanation regarding advances in HCV treatment leading to more tolerable and efficient therapies, accompanied by a leaflet with phone numbers and an open invitation for a hepatology clinic and treatment (free of charge), only 2 of 29 HCV antibody-positive individuals sought treatment at the medical center that was made available to them. In both cases, sustained virological response was achieved.

Discussion

In our prospective study, we report for the first time in Israel the real prevalence of hepatitis C in the urban PWUD population that was approached on the streets and needle exchange stations. This population is under-investigated worldwide due to challenging outreach while most of the existing data are based on screening that is limited to prisoners and opioid substitution therapy participants.\(^1\),\(^2\),\(^16\)-\(^18\),\(^21\) Although recruitment of PWUDs to participate in medical research is known to be challenging,\(^22\) the recruitment rate in our study was relatively high (40%) among this population, owing to professional and friendly communication by IATF volunteers and social workers. However, selection bias have be addressed, as further discussed in study limitation.

Our data indicate that HCV infection prevalence was 56%, similar to previous studies that were performed among PWUDs in the Middle East.\(^23\) Considering all our participants are defined as very high-risk population (homelessness and active drug use),\(^1\),\(^7\),\(^15\),\(^21\) we can estimate that HCV prevalence amongst the general Israeli population is likely to be lower.

Predictors of HCV positivity among PWUDs worldwide generally include increasing age, male gender, frequent and

| Table 1. Characteristics demographic. |
|-------------------------------------|
|                                    |
| **N=53 (%)**                        |
| **Sex**                             |
| Male                                |
| 42 (79.3)                           |
| Female                              |
| 11 (20.7)                           |
| **Age**                             |
| 20-30 years                         |
| 2 (4)                               |
| 30-50 years                         |
| 36 (70.6)                           |
| >50 years                           |
| 13 (25.5)                           |
| **Country of birth**                |
| Israel                              |
| 21 (42)                             |
| Former Soviet Union                 |
| 23 (46)                             |
| Other countries*                    |
| 6 (12)                              |
| **Native language**                 |
| Hebrew                              |
| 15 (28.3)                           |
| Russian                             |
| 23 (43.4)                           |
| Arabic                              |
| 8 (15.1)                            |
| Immigration† >10 years              |
| 23 (79.3)                           |

*Other countries include Jordan, Ethiopia, Sudan and Brazil.
†Twenty-nine immigrants in total.
When the denominator is less than the total n it is due to missing data.
Table 2. Risk factors associated with HCV infection.

|                     | HCV AB-POSITIVE (N=29) | HCV AB-NEGATIVE (N=23) | P-VALUE |
|---------------------|------------------------|------------------------|---------|
| Male gender, n (%)  | 20/29 (69)             | 21/23 (91.3)           | .08     |
| Age, years, mean (±SD) | 44.7 (±8.3)            | 43.7 (±11.2)           | .73     |
| Born in Israel, n (%) | 12/27 (44.4)           | 9/23 (39.1)            | .77     |
| Immigrants from Former Soviet Union vs Israelis, n (%) | 13/25 (52)         | 10/19 (52.6)           | .96     |
| Immigration Before 2010, n (%) | 15/16 (93.8) | 8/13 (61.5)          | .06     |
| Mean drug use, years (±SD) | 19.1 (±9.5)            | 13.4 (±10.8)          | .1      |
| IV Drug Use, n (%)  | 23/28 (82.1)           | 13/21 (61.9)           | .112    |
| Heroin use, n (%)   | 24/28 (85.7)           | 13/21 (61.9)           | .05     |
| Methadone use, n (%) | 3/29 (10.3)            | 2/23 (8.7)            | >.999   |
| One partner, n (%)  | 6/29 (20.7)            | 6/22 (27.3)            | .58     |
| Safe Sex, n (%)     | 4/28 (14.3)            | 5/21 (23.8)            | .47     |
| HIV positive, n (%) | 0/29                   | 1/22 (4.5)             | .43     |

Abbreviations: Ab, Antibodies; HCV, Hepatitis C Virus; HIV, Human Immunodeficiency Virus; IV, Intravenous; SD, standard deviation.
When the denominator is less than the total n it is due to missing data or subgroup analysis.
longer duration of injection, use of shared injecting equipment, living in an urban area, history of arrest and more. In our study we did not find an association between participant's age or gender to HCV positivity, nor between duration of injection and HCV exposure.

Established risk factors for HCV positivity in the general population in Israel include a history of blood product transfusion before 1990, history of drug use and being an immigrant from the former Soviet Union. In contrast to significantly higher HCV seroprevalence in immigrants from the former Soviet Union in the general population, there was no difference between Israeli-born or immigrants in PWUDs emphasizing the high significance and robustness of HCV transmission in drug users. Indeed, heroin use was the only significant predictor of HCV positivity in this dis-privileged population.

In accordance with results from previous studies, the awareness of study participants to their HCV status was high (72%) with the concordance of 91% between self-reported HCV positivity to laboratory results. Despite a high level of awareness and receiving detailed instruction about the option of getting free anti-HCV treatment including an open invitation to hepatology clinic, only 7% of participants sought treatment. This reluctance to receive treatment is concordant with additional studies. The reasons vary and may include fear of treatment side effects, underestimation of hepatitis C impact on the health due to lack of symptoms and misunderstanding of access to treatment steps. Depression and other psychiatric conditions which are associated with injection drug use, pose additional obstacle and significant treatment challenge, and may lead to decreased attention to personal health, including treatment rejection or deferral. Discrimination and stigmatization by medical staff toward actively PWUDs may also contribute to low treatment and recovery rates.

The main limitation of our study is its small sample size which may hinder accurate identification of risk factors for HCV infection. In addition, the fact that only 38% of those who approached IATF ambulance was tested may challenge the generalizability of the findings.

As the subjects who refused to be tested, did not fill out questionnaires, qualitative data for them are missing. Our observations suggest that the main reason for approaching the ambulance in subjects who refused testing was need for sterile needles and syringes. Thus, we can conclude that this group possessed the knowledge regarding blood-transmitted diseases and the ways of their prevention and still preferred to avoid HCV testing. We believe that the reasons for not seeking treatment in the subjects who refused undergoing testing, may be different from these of tested subjects and may include fear or ambivalence regarding HCV status, insecure immigration and legal status and mistrust in the medical system.

Information based on self-report may be unreliable, particularly when some participants were under illicit substance influence during questionnaire completion (hence were assisted by the IATF staff). In terms of reporting duration of drug use, types of drugs and mode of use, some participants were concerned that they could be identified by name or ID number, resulting in false or partial information being provided (for example, declaring an absence of drug use or marijuana as the primary substance rather than heroin use, respectively).
Conclusions
This study summarizes the results of proactive street HCV testing in the active PWUD population in Israel and demonstrates high HCV frequency and extremely low access to care in this population. Based on our results, awareness of HCV status is a contributing factor but not sufficient to lead to HCV eradication. Given our data, we believe that maximal efforts should be directed at improving understanding of therapeutic side effects, duration and outcomes, with an emphasis on comparison with outdated therapeutic approaches, to reduce stigma and misinformation regarding HCV treatment in individuals aware of HCV status or willing to engage with treatment. Additionally, further research should address the reasons for high level of avoiding HCV testing among this population and the ways to promote adapted and secure access to medical care for these individuals.

Acknowledgements
We would like to thank Israel AIDS Task Force staff and volunteers for their efforts to collect and share data during their social activities. AbbVie inc. generously provided OraQuick rapid tests.

Author Contributions
RL, OS, IB, MN and HK contributed to data acquisition. RL and HK contributed to writing the first draft, analysis of results and article revision. OS contributed to statistical analysis and article revision. AS and OM contributed to the article revision.

ORCID iD
Helena Katchman https://orcid.org/0000-0001-8490-1735

REFERENCES
1. Loebstein R, Mahagna R, Maor Y, et al. Hepatitis C, B, and Human Immunodeficiency Virus Infections in illicit drug users in Israel: Prevalence and risk factors. Isr Med Assoc J. 2008;10:775-778.
2. Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 2002;97:1289-1294.
3. World Health Organization. Global Hepatitis Report 2017: WHO Estimates of the Prevalence and Incidence of Hepatitis C Virus Infection by WHO Region. WHO, 2018.
4. United Nation Office on Drugs & Crime. World Drug Report 2017 (United Nations publication, Publication No. E.17.16). United Nation Office on Drugs & Crime, 2017.
5. UNAIDS. Joint United Nation Programme on HIV/AIDS, the GAP Report 2014. United Nations publication, 2014.
6. Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection in the United States and Dependent Areas, 2015 (Report No. 27/2016). Centers for Disease Control and Prevention, 2016.
7. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multisite systematic review. Lancet Glob Health. 2017;5:e1192-e1207.
8. Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol. 2019;71:281-288.
9. Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453-1464.
10. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012;32:88-102.
11. Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1221-1229.
12. Afifel N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Eng J Med. 2014;370:1889-1898.
13. Poordad F, Hezode C, Trinh R, et al. ABT-493+ribavirin and dasabuvir with ribavirin for hepatitis C with cirrhosis. New Eng J Med. 2014;370:1973-1982.
14. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756-1765.
15. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021: Towards Ending Viral Hepatitis (Report No. 06/2016). World Health Organization, 2016.
16. Cohen-Morenro R, Schif F, Levit S, Bar-Hamburger R, Strauss S, Neumark Y. Knowledge about Hepatitis C among methadone maintenance treatment patients in Israel. Subst Uz Misroz. 2010;45:58-70.
17. Lambdin BH, Lorivick J, Mbowamo JK, et al. Prevalence and predictors of HCV among a cohort of opioid treatment patients in dar es Salaam, Tanzania. Int J Drug Policy. 2017;45:64-69.
18. Maisa A, Semple S, Griffths A, et al. Risk behaviours of homeless people who inject drugs during an outbreak of hepatitis C, Northern Ireland, 2016-2017. J Viral Hepat. 2019;26:1377-1387.
19. Corbimb R, Raxzi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31:30-60.
20. Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. ‘hep C’s like the common cold’: Understanding barriers along the HCV care continuum among young people who inject drugs... Drug Alcohol Depend. 2018;190:246-254.
21. Boucher LM, Bayoumi AM, Mark AE, et al. Hepatitis C testing, status and treatment among marginalized people who use drugs in an inner city setting: an observational cohort study. Subst Uz Misroz. 2019;54:18-30.
22. Ahfad R, Goldenberg S, Wihal LA, et al. Establishing trust in HIV/HCV research among people who inject drugs (PWID): Insights from empirical research. PLoS One. 2018;13:e0208410.
23. Mahmud S, Mumtaz GR, Chemaitelly H, et al. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction. 2020;115:1244-1262.
24. Kerzman I, Green M, Shinar E. Risk factors for hepatitis C virus infection among blood donors in Israel; a case control study between native Israelis and immigrants from former Soviet Union. Transfus. 2007;47:1189-1196.
25. Nielsen S, Gasowski M, Wees B, et al. Concordance between self-reported and measured HIV and hepatitis C virus infection status among people who inject drugs in Germany. Hepatol Med Policy. 2016;11:1-7.
26. Young S, Wood E, Milloy MJ, et al. Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada. Subst Abuse. 2018;39:461-468.
27. Jordan AE, Masson CL, Mateu-Gelabert P, et al. Perceptions of drug users regarding hepatitis C screening and care: a qualitative study. Harm Reduc J. 2013;10:10.
28. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012;32:151-156.
29. Yeh SW, Holmes ACN, Saling MM, Everall IP, Nicoll AJ. Depression, fatigue, and neuropsychological deficits in chronic hepatitis C. Hepatol Int. 2012;6:294-304.
30. Genberg BL, Astemborski J, Treisman G, et al. Engagement in treatment for depression among people who inject drugs in Baltimore, Maryland. J Subst Abuse Treat. 2019;106:107-112.
31. Dinwiddie SH. Psychiatric comorbidity in people who inject drugs. Psychiatric Ann. 2017;47:27-32.
32. Meyerson BE, Russell DM, Kichler M, Atkin T, Fox G, Coles HB. I don’t even want to go to the doctor when I get sick now: Healthcare experiences and discrimination reported by people who use drugs. Arizona. Int J Drug Policy. 2021;59:1-6.